Downloads: 1
Original Research | Surgery | Volume 15 Issue 5, May 2026 | Pages: 478 - 483 | India
Outcome Analysis of Tamoxifen Versus Tamoxifen with Oopherectomy in Post-Mastectomy Hormone Positive Premenopausal Breast Cancer
Abstract: Introduction: Hormone receptor?positive (HR+) breast cancer is common in premenopausal women. The conventional adjuvant endocrine therapy is tamoxifen, but ovarian function suppression (OFS) by oophorectomy can enhance outcomes by reducing estrogen levels. The current research compares the effectiveness of tamoxifen alone versus tamoxifen and surgical oophorectomy in relation to survival and disease control in post-mastectomy HR+ premenopausal women. Methodology: A prospective randomized comparative clinical study was conducted at S.N. Medical College, Agra, from August 2023 to January 2025. Eighty premenopausal women with histologically confirmed ER/PR-positive breast cancer following mastectomy were randomly assigned to two groups: Group A received tamoxifen alone and Group B received tamoxifen plus bilateral salpingo-oophorectomy. The patients were observed for 18 months. The main results were disease-free survival (DFS) and overall survival (OS); the secondary results were loco-regional control, adverse effects, treatment compliance, cost-effectiveness, and quality of life. Results: Both groups were demographically and clinically comparable at baseline. Group B was marginally better in terms of 3-year DFS (60% vs. 50%) and OS (85% vs. 80%), but differences were not significant (p > 0.05). Loco-regional control was superior in Group B (92.5% vs. 87.5%). Oophorectomy cost and time were significantly higher. Side effect profiles and treatment compliance were comparable in both groups. Quality of life marginally but not significantly favored the oophorectomy group. Conclusion: Tamoxifen and oophorectomy confer marginal benefits in DFS and OS in HR+ premenopausal women following mastectomy. Trends in favor of benefit in high-risk patients, though not statistically significant, support tailored treatment planning.
Keywords: Tamoxifen, Oophorectomy, Hormone Receptor-Positive Breast Cancer, Premenopausal Women, Survival Outcomes
How to Cite?: Dr. Prof Richa Jaiman, Dr. Shivkant Mishra, Dr. Bhavna Verma, Dr. Puneet Shrivastava, Dr. Abhishek Pankaj, "Outcome Analysis of Tamoxifen Versus Tamoxifen with Oopherectomy in Post-Mastectomy Hormone Positive Premenopausal Breast Cancer", Volume 15 Issue 5, May 2026, International Journal of Science and Research (IJSR), Pages: 478-483, https://www.ijsr.net/getabstract.php?paperid=MR26505161147, DOI: https://dx.dx.doi.org/10.21275/MR26505161147